Pharmacology, Toxicology and Pharmaceutical Science

1. Inflammatory Arthritis 100%
2. Rheumatoid Arthritis 98%
3. Cohort Study 74%
4. Diseases 43%
5. Janus Kinase Inhibitor 41%
6. Adverse Event 38%
7. Monoclonal Antibody 33%
8. Randomized Controlled Trial 33%
9. Methotrexate 32%
10. Ecological Study 27%
11. Observational Study 26%
12. Gout 25%
13. Sarcoidosis 25%
14. Disease Modifying Antirheumatic Drug 20%
15. Remission 19%
16. Infection 19%
17. Placebo 17%
18. Tumor Necrosis Factor Inhibitor 15%
19. Abatacept 15%
20. Tofacitinib 15%
21. Biological Product 14%
22. Spondylarthritis 14%
23. Randomized Clinical Trial 13%
24. Monotherapy 13%
25. Prevalence 12%
26. Leflunomide 12%
27. Uveitis 12%
28. Pneumococcus Vaccine 12%
29. Antiviral Drug 12%
30. Pneumocystis Pneumonia 12%
31. Urate 12%
32. Coronavirinae 12%
33. Azathioprine 12%
34. Iridocyclitis 12%
35. Antirheumatic Agent 12%
36. Immunogenicity 12%
37. Infliximab 12%
38. Venous Thromboembolism 12%
39. Sepsis 12%
40. Sodium Valproate 12%
41. Necrosis 11%
42. Rituximab 10%
43. Pandemic 10%
44. Molnupiravir 9%
45. Etanercept 9%
46. Adalimumab 9%
47. Tumor Necrosis Factor 8%
48. Mixed Connective Tissue Disease 7%
49. Skin Cancer 6%
50. Disease Duration 6%